Therapeutic Antibody Series 2026

Biopharma Therapeutic antibodies are advancing rapidly, with innovations in discovery, engineering and manufacturing enabling more precise and complex biologics. From multispecifics to ADCs and immune-engaging approaches, developers face new opportunities and challenges in bringing optimized candidates to the clinic. In The Therapeutic Antibody Series 2026, experts will explore key innovations across the development pipeline, covering next-generation discovery tools such as single-cell and AI-assisted screening, alongside engineering strategies to improve specificity, stability and performance. The series will also address the transition to biomanufacturing and clinical development, including scalability, product quality and regulatory considerations, providing a clear view of how advanced antibody therapies are developed and delivered. Key Learning Objectives: - Accelerating antibody discovery using advanced screening technologies - Enhancing performance through engineering strategies such as bispecifics and ADCs - Key considerations for specificity, safety and developability - Best practices for scalable manufacturing and clinical translation Sinobiological